secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zeo ScientifiX, Inc. (ZEOX)
CIK:        0001557376
Form:       8-K
Filed at:   2025-02-18T23:59:59+00:00
Accession:  0001829126-25-001049
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ZEO ScientifiX appoints Dr. Peter A.M. Everts as Chief Scientific and Technology Officer
--------------------------------------------------------------------------------

- Dr. Everts brings 35+ years of experience in orthobiology, spine, wound care, and regenerative medicine.
- Previously CSO at EmCyte Corp and co-founder of Da Vinci Clinic, Netherlands; holds Ph.D. from University of Utrecht.
- ZEO is a clinical-stage biopharmaceutical company focused on biological therapeutics for degenerative diseases.
- Interim CEO Ian Bothwell says appointment underscores commitment to accelerating innovation and expanding regenerative therapies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557376/000182912625001049/0001829126-25-001049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557376/000182912625001049/zeoscientifix_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-25-001049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer